VibeOne Indication Prioritization
Challenges in the current process
It's slow
Assessing indications by hand takes months. The answer can be out of date before a decision is made.
It's fragmented
There are 20,000+ indications to explore. The data on each one is spread across papers, trials and databases.
It doesn't scale
Each round depends on consultants and subjective criteria, and the results are static once delivered.
Faster answers, in one place, on your terms
Answers in minutes, not months
One pharma client ran each indication analysis round in 10 days, 18x faster than its prior six-month process.
All the data in one place
Every indication in one ranked view. Each rank links back to its data, trials and papers.
Scale without added headcount
Rank indications against your team's own objective criteria, in place of a consulting-led process.
Configurable criteria
From modality fit to competition, patient population, clinical endpoints and custom dimensions. Rigorously score every indication.
Every indication in scope, sorted into tiers
Weight the criteria your way and the whole portfolio re-ranks against it.
20,000+ indications narrowed to a five-program pipeline
Portuguese pharma group, founded 1924. CNS and neuroscience focus.
Bial is building a rare disease business unit from scratch. They needed to find new therapeutic areas to develop novel drug programs.
VibeOne analyzed all 20,000+ known diseases and rigorously assessed each one against Bial's custom criteria, including biology, unmet need, clinical endpoint validation, competitive landscape and peak sales potential. It then helped the team deep dive on each priority.
Bial has initiated multiple new therapeutic programs from the analysis, including in disease areas introduced to them first by VibeOne.
“This was a game changer -- Now we are building drug programs in disease areas that we had never heard of until we used VibeOne.”